SECURITIES AND EXCHANGE COMMISSION
 
WASHINGTON, D.C. 20549
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of July 2017
_______________________
 
BioLineRx Ltd.
 (Translation of registrant’s name into English)
_______________________
 
2 HaMa’ayan Street
Modi’in 7177871, Israel
 (Address of Principal Executive Offices)
_______________________
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:        
 
Form 20-F ☑           Form 40-F ☐
 
Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:          
 
Yes ☐           No ☑
 

 
Further to its Current Report on Form 6-K dated May 30, 2017, the Registrant announces the following results of its Annual General Meeting of Shareholders which was held on July 5, 2016 at 3:00 p.m. (Israel time):
 
In respect of Proposal 1 – The required majority of shareholders who participated in the Meeting voted in favor of the election of Aharon Schwartz, Michael Anghel, B.J. Bormann, Raphael Hofstein and Sandra Panem as directors until the next annual general meeting of the Registrant’s shareholders or until their respective successors are duly elected.
 
In respect of Proposal 2 – The required majority of shareholders who participated in the Meeting voted in favor of the general terms of compensation for Mr. Philip Serlin, the Company’s Chief Executive Officer, and in favor of Mr. Serlin’s proposed equity compensation.
 
In respect of Proposal 3 – The required majority of shareholders who participated in the Meeting voted to approve an increase in the Registrant’s registered share capital and to amend the Registrant’s Articles of Association to reflect such increase.
 
In respect of Proposal 4 – The required majority of shareholders who participated in the Meeting voted in favor of the appointment of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, as the Registrant’s independent registered public accounting firm for the year ending December 31, 2017 and of authorizing the Audit Committee of the Board of Directors to fix the compensation of said auditors in accordance with the scope and nature of their services.
 
This Form 6-K is hereby incorporated by reference into all effective registration statements filed by the Company under the Securities Act of 1933.
 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
BioLineRx Ltd.
 
 
 
By:
/s/ Philip Serlin
 
   
Philip Serlin
 
   
Chief Executive Officer
 
 
Dated: July 5, 2017
 

BioLineRx (NASDAQ:BLRX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more BioLineRx Charts.
BioLineRx (NASDAQ:BLRX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more BioLineRx Charts.